1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Carvedilol |
| brand | String | Coreg, Coreg CR |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Beta blockers|Beta blocker (non-selective • with alpha-1 antagonism)]] • [[:Category:Antihypertensives|Antihypertensive]] • [[:Category:Heart failure medicines|Heart failure medicine]] |
| mechanism | String | '"`UNIQ--vote-00000015-QINU`"' CYP2D6 metabolism produces stereoselective clearance; CYP2D6 poor metabolizers have higher plasma exposure and may need lower doses'"`UNIQ--ref-00000016-QINU`"'. |
| uses | String | '"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"' |
| starting_dose | String | Heart failure: 3.125 mg PO BID, doubling every 2 weeks as tolerated to target 25 mg BID (50 mg BID if >85 kg). Hypertension: 6.25 mg PO BID, titrate to 25 mg BID |
| preparations | String | IR tablets 3.125, 6.25, 12.5, 25 mg; Coreg CR capsules 10, 20, 40, 80 mg (once-daily) |
| fda_max | String | 50 mg BID in heart failure (or once-daily equivalent CR); 25 mg BID in hypertension |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Antihypertensive effect within 1 week; heart-failure mortality benefit accrues over months of titration |
| duration | String | ~12 hours (IR); 24 hours (CR) |
| halflife | String | 7-10 hours'"`UNIQ--ref-0000001B-QINU`"' |
| bioavailability | String | ~25-35% (extensive first-pass), increased by food which slows absorption and reduces orthostatic risk'"`UNIQ--ref-0000001C-QINU`"' |
| pregnancy | String | Limited human data; β-blocker class effects include fetal growth restriction and neonatal bradycardia/hypoglycemia.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
